No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
90 (estimated)
Sponsor
Edwards Lifesciences · Industry
Who this trial is looking for
This trial is looking for people with heart failure to evaluate a new device. Participants will need to meet specific health criteria and may need to have recent heart failure events or treatments.
Are You a Good Fit for This Trial?
You may be able to join if
I have been diagnosed with heart failure (HFrEF)
I experience symptoms classified as NYHA Class II, III, or IVa
I have been hospitalized for heart failure in the past year
I have had an increase in heart failure treatment recently
I have elevated heart failure biomarker levels in the past 6 months
I have stable heart failure treatment for at least 6 months
You may not be able to join if
I have severe heart failure
I have active valve disease
I have a body mass index (BMI) of 45 or higher
I have had a heart attack or major cardiac procedure in the past 3 months
I have had a stroke or similar event in the past 6 months
I have renal insufficiency with high creatinine levels
I have had a recent infection requiring intravenous antibiotics
I have other serious heart function issues
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
The purpose of this study is to evaluate initial clinical safety, device functionality and effectiveness of the Edwards APTURE transcatheter shunt system.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Refined HFrEF Subgroup Inclusion Criteria:
* A primary diagnosis of HFrEF (LVEF ≤ 40%), and
* NYHA Class II, III, or IVa heart failure symptoms and
* Documentation of at least one of the following in the past 12 months, such as:
* Hospitalization for heart failure; or
* Increased treatment for…
Refined HFrEF Subgroup Inclusion Criteria:
* A primary diagnosis of HFrEF (LVEF ≤ 40%), and
* NYHA Class II, III, or IVa heart failure symptoms and
* Documentation of at least one of the following in the past 12 months, such as:
* Hospitalization for heart failure; or
* Increased treatment for heart failure, including intravenous (IV) or higher-dose diuretic therapy.
* Elevated heart failure biomarker levels (BNP or NT-proBNP) within the past 6 months.
Note: Participants with NYHA Class II symptoms must have both a recent heart failure worsening event and elevated biomarker levels. Participants with NYHA Class III or IVa symptoms must have either a recent heart failure worsening event or elevated biomarker levels.
* Stable Optimized GDMT - Maintained 6 months post-implant (includes stable GLP-1 RA)
Refined HFrEF Subgroup Exclusion Criteria:
* Severe HF defined as one or more of the following:
* Ambulatory NT-proBNP value \>5,000 pg/ml or BNP value \>1,600 pg/ml
* Left ventricular end-diastolic diameter (LVEDD) \>8 cm
* Left ventricular ejection fraction (LVEF) \< 20%
* ACC/AHA Stage D HF or non-ambulatory NYHA Class IV HF
* Inotropic infusion (continuous or intermittent) within the past 6 months
* Active listing on the cardiac transplant waiting list
* More than mild right ventricular dysfunction
* Valve disease
* Mitral regurgitation \> moderate
* Mitral stenosis \> mild
* Tricuspid regurgitation \> moderate
* Aortic regurgitation \> moderate
* Aortic stenosis \> moderate
* Body mass index (BMI) ≥45
* Myocardial infarction and/or any therapeutic invasive, non-valvular cardiac procedure within the past 3 months, or current indication for coronary revascularization
* Stroke, transient ischemic attack, deep vein thrombosis, or pulmonary embolus within the past 6 months
* Cardiac resynchronization therapy implanted within the past 12 months
* Renal insufficiency as determined by serum creatinine (sCr) level \>2.5 mg/dL or estimated glomerular filtration rate (eGFR) \<25 ml/min/1.73 m2
* Performance of the 6-minute walk test with a distance \<100 m or \>450 m
* Active endocarditis or infection requiring intravenous antibiotics within 3 months of scheduled index procedure
* Presence of one or more of the following resting hemodynamic findings:
1. Mean pulmonary capillary wedge pressure (PCWP) \>35 mmHg
2. Mean right atrial pressure (RAP) \>15 mmHg
3. Mean PCWP-mean RAP gradient \< 5 mmHg
4. Pulmonary vascular resistance (PVR) ≥5 Wood Units (WU)
5. Cardiac index \<1.8 L/min/m2
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.